A Phase 2 interventional study of IFN-α in Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Peking University People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.
Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 6 of the 15 other live ones, and was the 15th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 18–70
Peking University People's Hospital · Sites in China
Ages 18–70
Peking University People's Hospital · Sites in China
Peking University People's Hospital · Sites in China
Ages 6–60
Peking University People's Hospital · Sites in China
Ages 55–70
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 52 across the 17 interventional studies, 210 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
5 of the studies in Leukemia, Myeloid, Acute by Peking University People's Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06802718Phase 3Peking University People's HospitalInterferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | 2026-12 |
| NCT07449286Peking University People's HospitalIFN-α in Relapse Prevention. | 2026-12-31 |
| NCT07319793Peking University People's HospitalPre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT | 2027-01-01 |
| NCT06301425Peking University People's HospitalMRD Response-adapted Allo-HSCT for Adverse-risk AML | 2027-05-01 |
| NCT07925554Peking University People's HospitalInterferon-α Maintenance in Favorable-Risk AML | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No history of severe (GVHD), uncontrolled
GVHD, or severe systemic organ dysfunction:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IFN-α
Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and * 2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon- α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day * 100 after transplantation. The dose of interferon- α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
The incidence of relapse
Disease relapse was defined as blasts ≥ 5% post transplantation
Time frame: 1 year post HSCT
The incidence of positive minimal residual disease post allo-HSCT
Positive MRD was defined as leukemia-associated immunophenotyping (LAIPs) by flow cytometry
Time frame: 1 year post HSCT
The incidence of acute and chronic graft versus host disease (GvHD)
The severity of acute GvHD (aGvHD) and chronic GvHD (cGvHD) was evaluated according to standard criteria.
Time frame: aGvHD within 100 days and cCvHD within 1 year
The incidence of non-relapse mortality
The incidence of non-relapse mortality
Time frame: 1 year post HSCT
The probability of progression free survival
Survival without disease progression
Time frame: 1 year post HSCT
The probability of overall survival (OS)
OS was defined as the time from transplantation to death from any cause or to the last follow-up.
Time frame: 1 year post HSCT
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 9 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital →